Overview

LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Status:
Not yet recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

The hypothesis in this study was that ticagrelor switched to 60 mg after 1 month of standard dose, with antiplatelet activity that is not inferior to the standard dose and better than 75 mg clopidogrel for patients with ACS after PCI.

Phase:

Phase 4

Details

Lead Sponsor:

Beijing Anzhen Hospital

Treatments:

Clopidogrel
Ticagrelor